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(Corgenix). In addition, disease activity (DAS28 or BASDAI),
CRP, IgM rheumatoid factor, anti-CCP, and lipid levels (total
cholesterol, TC; LDL-C, HDL-C and triglyceride) were also
assessed. Assessments were performed at baseline, as well as 6
and 12 months after treatment initiation.
Results Anti-TNF treatment was highly effective in both dis-
eases, as the mean DAS28 decreased from 6.32 to 3.16 (p =
0.02) in RA, mean BASDAI decreased from 5.87 to 1.84 (p <
0.001) in AS. In RA, AS and the mixed arthritis population (n =
43) baseline oxLDL/beta2gpI levels were 0.235 ± 0.1, 0.245 ±
0.1 and 0.238 ± 0.1, respectively. There were no significant dif-
ferences between RA and AS patients. In RA, ETN/CZP treat-
ment resulted in non-significant decreases in complex levels after
6 months (0.214 ± 0.1) and 12 months (0.206 ± 0.1). In AS,
oxLDL/beta2gpI complex levels did not change after 6 months
of ETN therapy, but significantly decreased after one year
(0.195 ± 0.1; p = 0.01). In the RA+AS population, anti-TNF
treatment significantly decreased oxLDL/beta2gpI levelés after
12 months (0.203 ± 0.1, p = 0.02). In addition, baseline
oxLDL/beta2gpI complex levels positively correlated with TC
(RA: r = 0.563, p = 0.002; AS: r = 0.542, p = 0.049; RA+AS:
r = 0.532, p < 0.001), and LDL-C (RA: r = 0.630, p < 0.001;
AS: r = 0.756, p = 0.004; RA+AS: r = 0.648, p < 0.001) in
both diseases. Circulating oxLDL/beta2gpI levels did not corre-
late with DAS28, BASDAI or CRP.
Conclusions In a mixed cohort of RA and AS patients, anti-TNF
therapy suppressed the circulating levels of oxLDL/beta2gpI
complexes, markers of atherosclerosis and vascular disease in
SLE or APS. Moreover, oxLDL/beta2gpI levels correlated with
TC and LDL-C in arthritides. oxLDL/beta2gpI complexes do not
seem to be markers of disease activity in RA or AS.
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Introduction Semaphorin 3A (sema3A) plays a regulatory role in
immune responses, mainly affecting the activation of regulatory
T cells. It has been found to correlate with disease activity in
rheumatoid arthritis and systemic lupus erythematosus (SLE).
Aim To investigate the expression of sema3A in patients with
systemic sclerosis (SSc) compared to healthy controls and SLE
disease controls and to correlate its expression with clinical
characteristics.
Methods 27 SSc patients, 42 SLE patients and 18 healthy con-
trols were enrolled. Serum level of sema3A was measured by
ELISA and expression of sema3A on regulatory T cells was eval-
uated by FACS analysis. SSc patients were evaluated for demo-
graphics, clinical manifestations, routine laboratory results,
nailfold videocapillaroscopy patterns, pulmonary function tests,
echocardiograms, modified Rodnan skin score (mRSS) and dis-
ease activity and severity scores.
Results Serum levels of semaphorin 3A were lower in SSc com-
pared to healthy controls 14.38 ± 5.7 ng/ml vs. 27.14 ± 8.4 ng/
ml, p < 0.0001 and similar to SLE 15.7 ± 4.3 ng/ml. The
expression of semaphorin 3A on regulatory T cells was also
lower in SSc compared to healthy controls 61.7 ± 15.7% vs.
88.7 ± 3. 7% (p < 0.0001). Semaphorin 3A serum level
inversely correlated with the duration of disease; r = -0.4, p =
0.036 and with low C4 level r = 0.66 p = 0.026. SCL-70 anti-
body positivity was associated with a lower semaphorin 3A level
in serum (difference in mean of 3.44 p = 0.06).
Conclusion Sema3A expression is low in SSc serum and more
specifically on regulatory T cells. This may help explain the
reduced activation of regulatory T cells in SSc, contributes to
our understanding of the pathogenesis of the disease and may
serve as a future target for treatment.
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Background and objectives Accelerated atherosclerosis, increased
cardiovascular (CV) morbidity and mortality have been associ-
ated with rheumatoid arthritis (RA). In single SNP studies,
CD40, HLADRB1, MTHFR, SMAD3 and possibly other alleles
have been associated with cardiovascular disease (CVD) or vascu-
lar pathophysiology in RA. Endothelial dysfunction, carotid athe-
rosclerosis and arterial stiffness that may predict the
development of CVD are assessed by bracial artery flow-medi-
ated vasodilation (FMD), common carotid intima-media thick-
ness (ccIMT) and arterial pulse-wave velocity (PWV),
respectively. In this study, we wished to determine expression
profiles of multiple genes that may differentiate between physio-
logical and pathological vascular function in RA.
Patients and methods Altogether 16 RA patients were recruited.
FMD, ccIMT and PWV were assessed in all patients using
standard B-mode ultrasound techniques. FMD < 6%, ccIMT
> 0.6mm and PWV > 9 m/sec were considered abnormal.
Peripheral blood mononuclear cell samples were obtained and
used in microarray. The signature of those genes were deter-
mined by principal component analysis (PCA) and hierarchic
clustering (GeneSpring software), which significantly differenti-
ated patient subsets with normal vs. abnormal FMD, ccIMT
and PWV.
Results Among RA patients, 11 had low (impaired) and 5 had
normal FMD, 11 had high (increased) and 5 had normal ccIMT
and 9 had high (increased) and 7 had normal PWV. Altogether
20 genes differentiated patients with low vs. normal FMD. Alto-
gether 33 genes separated high vs. normal PWV. Finally, 240
genes differentiated increased vs. normal ccIMT.
Conclusions Using microarray, genetic signatures may differenti-
ate RA patients with and without vascular pathology.
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